Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hong Jing Qi Wei is a Traditional Chinese Medicine (TCM) formula developed by Xiyuan Hospital of the Chinese Academy of Chinese Medical Sciences, specifically designed to treat type 2 diabetes mellitus and its associated complication, diabetic erectile dysfunction (DED). The formula is centered around *Rhodiola rosea* (Hongjing Tian) and is typically administered as an oral hospital preparation. Its therapeutic effects are mediated through the enhancement of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the corpus cavernosum, which facilitates smooth muscle relaxation and improved blood flow. Additionally, it exhibits potent antioxidant properties and inhibits the formation of advanced glycation end-products (AGEs), thereby protecting vascular and neural tissues from chronic hyperglycemic damage. Clinical research at Xiyuan Hospital has demonstrated its efficacy in improving erectile function scores and metabolic parameters in diabetic patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hong Jing Qi Wei.